四异丙基偶氮二甲酰胺 | 155877-06-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 四异丙基偶氮二甲酰胺
• 中文别名: N,N-二异丙基偶氮二甲酰胺
• 英文名称: Tetraisopropylazodicarboxamid
• 英文别名: (3E)-3-[di(propan-2-yl)carbamoylimino]-1,1-di(propan-2-yl)urea
• CAS: 155877-06-8
• 化学式: C₁₄H₂₈N₄O₂
• 分子量: 284.4
• InChiKey: NKMKDPVCESDJCN-FOCLMDBBSA-N

物化性质

• 沸点：
  341.2±25.0 °C(Predicted)
• 密度：
  1.02±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  65.3
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• METHOD FOR PREPARING AFATINIB AND INTERMEDIATE THEREOF
  申请人：Xu Xuenong

  公开号：US20160083373A1

  公开（公告）日：2016-03-24

  Revealed in the present invention is a method for preparing Afatinib (I): using 2-nitrile-4-[4-(N,N-dimethylamino)-I-oxo-2-buten-I-yl]amino-5-[(S)-(tetrahydrofuran-3-yl)oxy]aniline (II) and 4-fluoro-3-chloroaniline (III) as starting materials, and respectively performing a condensation and cyclization reaction with N,N-dimethylformamide dimethyl acetal (IV) to prepare Afatinib (I), wherein the method significantly reduces the manufacturing steps of Afatinib and greatly lower the costs. In addition, also provided in the present invention is a method for preparing an intermediate of Afatinib, wherein the method has a stable process, uses readily available starting materials, has a low cost, and all the reactions are classic reactions, suitable for meeting amplification requirements in the industry.

  本发明揭示了一种制备阿法替尼（I）的方法：使用2-腈基-4-[4-(N,N-二甲基氨基)-1-氧代-2-丁烯-1-基]氨基-5-[(S)-(四氢呋喃-3-基)氧基]苯胺（II）和4-氟-3-氯苯胺（III）作为起始原料，分别与N,N-二甲基甲酰胺二甲基缩醛（IV）进行缩合和环化反应制备阿法替尼（I），该方法显著减少了阿法替尼的制造步骤，大大降低了成本。此外，本发明还提供了一种制备阿法替尼中间体的方法，该方法具有稳定的工艺过程，使用易得的起始原料，成本低廉，并且所有反应均为经典反应，适合满足行业中的扩产需求。
• DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE AND PHARMACEUTICALS CONTAINING THE SAME
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：US20160002251A1

  公开（公告）日：2016-01-07

  The present invention provides a dihydropyridazine-3,5-dione derivative or a salt thereof, or a solvate of the compound or the salt, a pharmaceutical drug, a pharmaceutical composition, a sodium-dependent phosphate transporter inhibitor, and a preventive and/or therapeutic agent for hyperphosphatemia, secondary hyperparathyroidism, chronic renal failure, chronic kidney disease, and arteriosclerosis associated with vascular calcification comprising the compound as an active ingredient, and a method for prevention and/or treatment.

  本发明提供了一种二氢吡啶嗪-3,5-二酮衍生物或其盐，或化合物或盐的溶剂化合物，一种药物，一种药物组合物，一种钠依赖性磷酸盐转运体抑制剂，以及作为活性成分的化合物的高磷血症、继发性甲状旁腺功能亢进症、慢性肾功能衰竭、慢性肾病和与血管钙化相关的动脉硬化的预防和/或治疗剂，以及预防和/或治疗的方法。
• [EN] PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF VOXELOTOR<br/>[FR] PROCÉDÉ ET INTERMÉDIAIRES POUR LA SYNTHÈSE DE VOXÉLOTOR
  申请人：BIONICE S L U

  公开号：WO2020127945A1

  公开（公告）日：2020-06-25

  The invention relates to a process for the preparation of Voxelotor, or a salt or solvate thereof, according to the following scheme (Formula 1).

  这项发明涉及根据以下方案（公式1）制备Voxelotor或其盐或溶剂的过程。
• NEW PROCESS
  申请人：ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD

  公开号：US20150210632A1

  公开（公告）日：2015-07-30

  The invention relates to a new enantioselective process for producing useful intermediates for the manufacture of NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a γ-amino-δ-biphenyl-α-methylalkanoic acid, or acid ester, backbone.

  本发明涉及一种新的手性选择性工艺，用于生产制造NEP抑制剂或其前药的有用中间体，特别是包含γ-氨基-δ-联苯-α-甲基链烷酸或酸酯骨架的NEP抑制剂。
• Novel Compounds
  申请人：Gottschling Dirk

  公开号：US20120088755A1

  公开（公告）日：2012-04-12

  The present invention relates to the new compounds of general formula I wherein A, U, V, X, Y, R 1 , R 2 and R 3 are defined as stated hereinafter, the tautomers, the isomers thereof, the diastereomers, the enantiomers, the hydrates, the mixtures and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, their use and processes for preparing them.

  本发明涉及一般式I的新化合物，其中A、U、V、X、Y、R1、R2和R3的定义如下所述，其互变异构体、异构体、二对映异构体、对映体、水合物、混合物及其盐以及该盐的水合物，特别是与无机或有机酸或碱形成的生理上可接受的盐，含有这些化合物的药物，它们的用途以及制备它们的方法。